Clinical outcomes and safety of preservative-free diclofenac sodium eye drops in SPT-assisted transepithelial photorefractive keratectomy
Frontiers in Pharmacology · 15.04.2026 · 17
DOI: 10.3389/fphar.2026.1781133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.04.2026. Verfasst von Huang Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Zhongshan Torch Development Zone People's Hospital, Zhongshan, Guangdong, China. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Early postoperative pain and epithelial recovery remain important determinants of patient experience after surface ablation refractive surgery. Evidence comparing topical nonsteroidal anti-inflammatory drug (NSAID) options in Smart Pulse Technology (SPT)-assisted transepithelial photorefractive keratectomy (TransPRK) is limited.
Methods
This retrospective cohort study included consecutive patients who underwent SPT-assisted TransPRK between January 2022 and December 2025. Patients received either standard postoperative care plus pranoprofen 0.1% eye drops (control group) or preservative-free diclofenac sodium 0.1% eye drops (PF diclofenac; observation group), administered four times daily for 3 days. Pain was assessed using the visual analog scale (VAS; 0–10) at 2, 24, 48, and 72 h. Secondary outcomes included time to complete epithelialization, time to bandage contact lens (BCL) removal, corneal haze grading, ocular surface and inflammatory signs, and adverse events.
Results
A total of 239 patients were analyzed (control, n = 118; observation, n = 121). The observation group had significantly lower VAS pain scores at 2 h (5.40 ± 1.70 vs. 4.80 ± 1.60; P = 0.005), 24 h (4.20 ± 1.60 vs. 3.40 ± 1.50; P < 0.001), 48 h (2.80 ± 1.30 vs. 2.10 ± 1.20; P < 0.001), and 72 h (1.60 ± 1.00 vs. 1.20 ± 0.90; P = 0.001). A higher proportion of patients in the observation group achieved mild pain (VAS ≤ 3) at 24 h (53.7% vs. 38.1%; P = 0.016). Time to complete epithelialization (4.05 ± 0.88 vs. 4.32 ± 0.92 days; P = 0.021) and BCL removal (4.25 ± 0.90 vs. 4.56 ± 0.98 days; P = 0.012) were shorter in the observation group. Corneal haze and adverse events were comparable between groups, and no serious adverse events were observed.
Conclusion
In SPT-assisted TransPRK, PF diclofenac was associated with improved early pain control and modestly faster epithelial recovery, without detectable differences in haze or short-term safety compared with pranoprofen.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Zhongshan Torch Development Zone People's Hospital, Zhongshan, Guangdong, China.
Zitieren
APA
Zhang, H., Li, M. M., & Qiu, S. (2026). Clinical outcomes and safety of preservative-free diclofenac sodium eye drops in SPT-assisted transepithelial photorefractive keratectomy. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1781133
Vancouver
Zhang H, Li MM, Qiu S. Clinical outcomes and safety of preservative-free diclofenac sodium eye drops in SPT-assisted transepithelial photorefractive keratectomy. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1781133
BibTeX
@article{Zhang2026,
author = {Zhang, Huang and Li, Ming-Ming and Qiu, Shuang},
title = {Clinical outcomes and safety of preservative-free diclofenac sodium eye drops in SPT-assisted transepithelial photorefractive keratectomy},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1781133}
}
EUVIMED